Teva Pharmaceutical Industries (TEVA) PT Set at $25.00 by Cantor Fitzgerald
Teva Pharmaceutical Industries (NYSE:TEVA) received a $25.00 target price from stock analysts at Cantor Fitzgerald in a research note issued to investors on Friday. The brokerage presently has a “hold” rating on the stock. Cantor Fitzgerald’s price target suggests a potential upside of 4.17% from the company’s current price.
The analysts wrote, “We rate TEVA 12-month price target of $25. We like Teva’s stock and believe that there is a lot of value to be unlocked, but that it will take time for new leadership to return the business to growth. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $25.””
Other equities analysts also recently issued reports about the stock. Zacks Investment Research raised shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $27.00 price target on the stock in a report on Monday, July 9th. Citigroup boosted their price target on shares of Teva Pharmaceutical Industries from $25.00 to $27.00 and gave the stock a “buy” rating in a report on Wednesday, June 27th. Goldman Sachs Group boosted their price objective on Teva Pharmaceutical Industries from $25.00 to $28.00 and gave the company a “buy” rating in a research note on Monday, June 25th. Mizuho restated a “buy” rating and issued a $27.00 price objective on shares of Teva Pharmaceutical Industries in a research note on Thursday, August 2nd. Finally, ValuEngine upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research note on Tuesday, August 7th. Seven research analysts have rated the stock with a sell rating, sixteen have given a hold rating and seven have given a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $21.07.
Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings data on Thursday, August 2nd. The company reported $0.78 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.64 by $0.14. The firm had revenue of $4.70 billion for the quarter, compared to the consensus estimate of $4.75 billion. Teva Pharmaceutical Industries had a negative net margin of 47.98% and a positive return on equity of 19.92%. The business’s revenue for the quarter was down 17.8% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.02 EPS. sell-side analysts predict that Teva Pharmaceutical Industries will post 2.67 EPS for the current year.
In related news, EVP Sven Dethlefs acquired 2,000 shares of the company’s stock in a transaction dated Friday, August 3rd. The stock was purchased at an average price of $21.92 per share, with a total value of $43,840.00. Following the completion of the purchase, the executive vice president now owns 6,445 shares in the company, valued at approximately $141,274.40. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Iris Beck Codner sold 4,165 shares of the stock in a transaction that occurred on Thursday, August 9th. The shares were sold at an average price of $22.70, for a total value of $94,545.50. Following the sale, the executive vice president now directly owns 8,290 shares of the company’s stock, valued at approximately $188,183. The disclosure for this sale can be found here. Corporate insiders own 0.43% of the company’s stock.
Institutional investors have recently made changes to their positions in the stock. Global Financial Private Capital LLC raised its holdings in shares of Teva Pharmaceutical Industries by 92.2% during the second quarter. Global Financial Private Capital LLC now owns 23,632 shares of the company’s stock valued at $575,000 after acquiring an additional 11,335 shares in the last quarter. Benjamin F. Edwards & Company Inc. raised its holdings in Teva Pharmaceutical Industries by 553.3% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 22,361 shares of the company’s stock worth $544,000 after purchasing an additional 18,938 shares in the last quarter. Sei Investments Co. raised its holdings in Teva Pharmaceutical Industries by 26.8% in the second quarter. Sei Investments Co. now owns 162,241 shares of the company’s stock worth $3,946,000 after purchasing an additional 34,305 shares in the last quarter. Toronto Dominion Bank bought a new position in Teva Pharmaceutical Industries in the second quarter worth $669,000. Finally, Raymond James Financial Services Advisors Inc. raised its holdings in Teva Pharmaceutical Industries by 25.5% in the second quarter. Raymond James Financial Services Advisors Inc. now owns 83,473 shares of the company’s stock worth $2,030,000 after purchasing an additional 16,946 shares in the last quarter. Institutional investors own 64.52% of the company’s stock.
Teva Pharmaceutical Industries Company Profile
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.
Read More: Growth Stocks
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.